Deloitte China assists listing of BrainAurora on SEHK

Deloitte China supported the listing of BrainAurora Medical Technology Limited (BrainAu, stock ticker: 06681.HK) on the Stock Exchange of Hong Kong (SEHK) on 8 January 2025. BrainAu is the first Chinese company that developed medical grade digital therapeutics (DTx) products for cognitive impairment, and also the 1st Chinese developer of DTx for cognitive impairment that got listed in Hong Kong.

BrainAu offered about 181 million shares at HKD3.22 each, raising around HKD583 million.

(From left) Aimee Shi, Deloitte China’s Audit and Assurance (A&A) senior manager; Eleanor Hu, Northern Region Hong Kong Technical leader of Capital Market Services Group (CMSG); Rossana Ley, National A&A leader; Xiaoyi Wang, Executive Director and Chief Executive Officer of BrainAu; Zheng Tan, Chairman of the Board, Executive Director and Chief Strategy Officer of BrainAu; Wang Junjie, Chief Financial Officer of BrainAu; Ernest Lee, Deloitte China’s Technical partner, and a member of the Listing Committee of the SEHK; Jacky Mak, CMSG's Northern Region Offering Services partner and Olivia Jiang, A&A senior manager attend BrainAu’s listing ceremony

(From left) Zhang Maowen, senior finance manager of BrainAu; Olivia Jiang, Eleanor Hu, Rossana Ley, Junjie Wang, Xiaoyi Wang, Jacky Mak, Ernest Lee, Aimee Shi and Yaoyu Li, Senior Finance Manager of BrainAu attend BrainAu’s listing ceremony

(From left) Aimee Shi, Eleanor HuJacky Mak and Olivia Jiang attend BrainAu’s listing ceremony

Client overview

Founded in 2012, BrainAu’s product pipeline covers both the assessment and intervention of a broad range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, psychiatric disorders and child development deficiencies, among others. The Brain Function Information Management Platform Software System, the core product of BrainAu, is an evidence-based, medical-grade DTx product, and the first cognitive impairment DTx product in China that has received regulatory approval. The System had been commercialized for eight indications from four major types of cognitive impairment and is under development for several other cognitive impairment indications as of the Latest Practicable Date.

BrainAu is committed to establishing cognitive centers in over 2,100 public hospitals across China and promoting the development of cognitive impairment DTx market in China.

Source: BrainAu’s IPO prospectus published on 30 December 2024

Deloitte’s role

As one of the core service institutions, Deloitte China has been deeply involved in the entire process of offering reporting, fundraising and listing of this IPO. Our engagement team maintained a dedicated and focused attitude with a high-quality philosophy of diligence and excellence. We delivered the highest quality of professional services using our rich industry experience to assist BrainAu complete its filing work smoothly at every stage of Iisting. We also cooperated with all related professional parties to achieve BrainAu's listing on SEHK.

Deloitte China congratulates BrainAu for its successful listing on SEHK. We will continue to provide high quality professional services and outstanding resources integration to assist more clients to take one-step ahead in today's increasingly competitive and complex business environment.